GBIO May 2024 5.000 put
| Previous Close | 1.7000 |
| Open | 1.6000 |
| Bid | 0.0000 |
| Ask | 1.7500 |
| Strike | 5.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 1.6000 - 1.6000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 11 |
ZacksGeneration Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
Generation Bio (GBIO) delivered earnings and revenue surprises of -211.11% and 34.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireGeneration Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
- Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP) - ASGCT poster presentations described immune-quiet DNA (iqDNA) as partially single-stranded, produced by flexible, scalable, proprietary rapid enzymatic synthesis - Cash balance of $233.9 million still expected to fund operations into 2H 2027 CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechno
- GlobeNewswire
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
Data presented show immune-quiet DNA (iqDNA) is a partially single-stranded DNA cargo that maintains expression while evading innate immune sensorsRapid enzymatic synthesis continues to improve iqDNA performance through process development and the identification of novel structural elements Data on cell-targeted LNP (ctLNP) in vivo delivery of therapeutic transgenes to T cells to be discussed in an oral presentation on Saturday, May 11 CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Generatio
